Higher Buprenorphine Doses Improve Opioid Treatment Retention

A new study is reshaping how clinicians think about medication-assisted treatment for opioid use disorder, and the findings could directly impact how long patients stay in care and stay safe.

Patients prescribed 17 to 24 milligrams per day of buprenorphine averaged 190 days in treatment, compared to just 90 days for those receiving 8 milligrams or less, a difference that can mean everything in recovery from opioid dependence.

Why Medication-Assisted Treatment Retention Matters

Staying in treatment isn’t a bureaucratic milestone, it’s a survival metric. Remaining in opioid use disorder care reduces overdose risk and provides a foundation for recovery.

Every day a patient stays engaged with a medical detox program or MAT provider is a day they are not exposed to an unregulated street supply where fentanyl, xylazine and other adulterants have made overdose risk unpredictable.

Buprenorphine is one of the three FDA-approved medications for opioid use disorder, alongside methadone and naltrexone.

It works differently from full opioid agonists. Buprenorphine only partially activates opioid receptors, providing enough stimulation to prevent withdrawal and cravings without producing euphoria.

It also acts as a blocker, preventing other opioids from binding to receptors and causing euphoric effects, which reduces the incentive to use while on the medication.

What the New Research Found

Researchers at the University of Pennsylvania studied approximately 5,000 adults enrolled in Medicaid in Philadelphia who were receiving buprenorphine for opioid use disorder.

Patients who received higher doses, typically 17 to 24 milligrams per day, and sometimes more, stayed in treatment significantly longer than those on medium doses of 9 to 16 milligrams or lower doses of 8 milligrams. You can explore various detox centers in Philadelphia to find an option that supports your recovery needs.

The study also uncovered a troubling racial disparity. Black patients were less likely than white patients to receive the higher 17 to 24 milligram prescriptions, potentially reflecting prescriber preferences, health care inequities or misconceptions about safe dosing among both patients and clinicians.

These disparities matter because equal access to effective dosing in medication-assisted treatment is central to equitable care. Patients who are systematically undertreated face greater risk of relapse, overdose and dropout from medical detox programs.

The FDA Updated Its Guidance in December 2024

For years, a “target dose” of 16 milligrams was embedded in buprenorphine prescribing language, and many clinicians and insurers interpreted it as a ceiling.

In December 2024, the FDA updated its recommendations, removing the phrase “target dose” from the drug label and clarifying that doses above 24 milligrams, while not yet studied in randomized trials, may be appropriate for some patients.

This change has real consequences for medical detox and opioid treatment programs. The previous language had discouraged providers from prescribing what patients actually needed, particularly in cities like Philadelphia where the street opioid supply has become increasingly potent and unpredictable.

In this environment, standard buprenorphine doses may simply not be sufficient to stabilize withdrawal and prevent patients from using again.

Understanding Buprenorphine in Medical Detox

Buprenorphine (often dispensed as Suboxone, which combines buprenorphine with naloxone) is a cornerstone of opioid medical detox and long-term MAT. It is used both in inpatient detox settings and in outpatient medication-assisted treatment programs.

Clinicians use it to manage opioid withdrawal symptoms during the acute detox phase and as ongoing maintenance therapy to prevent relapse.

Because it is a partial agonist with a ceiling on respiratory depression, it carries a significantly lower overdose risk than full opioid agonists like methadone when used as prescribed, though it still requires medical supervision, particularly during induction.

Finding Opioid Medical Detox

If you or someone you love is dependent on opioids, getting into medically supervised detox is the safest first step.

Attempting to stop opioids abruptly without support is dangerous, withdrawal symptoms can drive relapse and, in the context of today’s fentanyl-saturated drug supply, a single relapse can be fatal.

You can search detox.com’s directory to find a detox treatment center near you. Call 800-996-6135(Sponsored) to speak with a treatment advisor to get started with your recovery today.